HAMLET (protein complex)

Last updated

HAMLET (Human Alpha-lactalbumin Made LEthal to Tumor cells) is a complex between alpha-lactalbumin and oleic acid that has been shown in cell culture experiments to induce cell death in tumor cells, but not in healthy cells.

Contents

HAMLET is a possible chemotherapeutic agent with the ability to kill cancer cells. [1] Alpha-lactalbumin is the primary protein component of human milk. In a 1995 study, it was discovered by Swedish scientist Anders Håkansson (Anders Hakansson) [2] that multimeric alpha-lactalbumin (MAL), a compound isolated from a fraction of human milk called casein, induced what appeared to be apoptosis in human lung carcinoma cells, pneumococcus bacteria, and other pathogens, while leaving healthy, differentiated cells unaffected. It has been the perfect cure in this case. [2] The active component responsible for the tumoricidal activity was found in 2000 and found to be a complex of alpha-lactalbumin and oleic acid. [3]

Endogenous human alpha-lactalbumin is complexed with a calcium ion and serves as a cofactor in lactose synthesis, but has no tumoricidal properties. The alpha-lactalbumin must be partially unfolded to allow for release of the calcium ion and replacement with an oleic acid molecule. The partially folded conformation is essential to the cytotoxicity of HAMLET, as mutagenesis studies have shown that completely unfolded alpha-lacalbumin does not retain the functional properties of HAMLET. [4] [5] The oleic acid is necessary for stabilizing this molecule in this partially unfolded state. Over the past several years, additional work has further characterized the structure and function of HAMLET and its clinical applications are currently under investigation. However, in order to develop effective therapies, more must be known about the mechanism of action of HAMLET.

Mechanism of action

HAMLET carries out independent attacks on many distinct cell organelles, including mitochondria, proteasomes, and histones, and interferes with cell processes such as macroautophagy. It has been shown that HAMLET binds to the cell surface and rapidly invades cells, with tumor cells taking up far more protein than healthy, differentiated cells. The mechanism of its entry is poorly understood, but recent studies indicate that the oleic acid in the HAMLET complex interacts with phosphatidylserine and o-glycosylated mucin on the plasma membrane, both of which are expressed in greater amounts on the plasma membrane of tumor cells, possibly providing for HAMLET’s specificity. [6]

One of the most prominent targets of HAMLET once inside the cell is the mitochondrion. Electron microscopy has revealed physical damage to the mitochondrial membranes and assays have found cytochrome c release and activation of the caspase cascade, the most notable ones being caspases 2, 3, and 9. [7] Cell death is not prevented by caspase inhibitors, or by BCL-2 or p53 mutagenesis, indicating that the traditional apoptotic caspase cascade is not the ultimate cause of cell death.[ citation needed ]

Another target of HAMLET is the proteasome. 26S proteasomes are activated in response to large quantities of unfolded HAMLET protein in the cytoplasm, but degradation of HAMLET by the proteasome is unusually slow. Furthermore, in vitro studies have shown that HAMLET is capable of binding the catalytic 20S subunit of the proteasome and disabling its enzymatic activity, an effect that has never before been demonstrated for any protein. However, proteasome inhibition alone does not seem to be responsible for HAMLET-induced cell death, as proteasome inhibitors have been shown to reduce the cytotoxicity of HAMLET. [8]

HAMLET also targets the nucleus, where it interacts with histones to interfere with transcriptional processes. Studies have shown that HAMLET is mostly localized to the nucleus within one hour of invading a tumor cell. Hamlet has been shown to bind with high affinity to individual histone proteins, to be specific H2a, H2b, H3, and H4, as well as entire nucleosomal units. This interaction irreversibly blocks transcription and leads to activation of p53. [9] This process has been demonstrated to be similar to histone hyperacetylation and it was found that histone de-acetylase inhibitors potentiated the effects of HAMLET. [10]

HAMLET cells showed the physiological characteristics of macroautophagy, a process in which cellular components are sequestered in double membrane-bound vesicles that fuse with lysosomes for degradation. Cells also showed decreased levels of mTOR, a known inhibitor of macroautophagy. HAMLET cells and cells under conditions of amino acid starvation (a known initiator of macroautophagy) showed similar expression patterns of autophagocytotic proteins and responded equally well to addition of macroautophagy inhibitors. [11]

Research

Antibiotic adjuvant

While HAMLET [ permanent dead link ] on its own is not active against most bacteria, when present together with antibiotics, HAMLET may help. Specifically, HAMLET can make MRSA bacteria sensitive against methicillin, vancomycin, gentamicin and erythromycin [12]

Tumors

Research is being conducted to determine if this could be a possible treatment for cancer. [1] Animal models of glioblastoma have been studied with tentative success. [1] The first human trial of the therapy was on benign skin growths known as warts and showed positive outcomes without any side effects. [1]

It is being studied in carcinomas of the lung, throat, kidney, colon, bladder, prostate, and ovaries, as well as melanomas, glioblastomas, and leukemias. A study of bladder cancer in a mouse found it caused shedding of TUNEL-positive cancer cells into the urine, with no adverse side-effects on healthy cells. [13]

See also

Related Research Articles

<span class="mw-page-title-main">Apoptosis</span> Programmed cell death in multicellular organisms

Apoptosis is a form of programmed cell death that occurs in multicellular organisms and in some eukaryotic, single-celled microorganisms such as yeast. Biochemical events lead to characteristic cell changes (morphology) and death. These changes include blebbing, cell shrinkage, nuclear fragmentation, chromatin condensation, DNA fragmentation, and mRNA decay. The average adult human loses 50 to 70 billion cells each day due to apoptosis. For the average human child between 8 and 14 years old, each day the approximate loss is 20 to 30 billion cells.

Experimental cancer treatments are mainstream medical therapies intended to treat cancer by improving on, supplementing or replacing conventional methods. However, researchers are still trying to determine whether these treatments are safe and effective treatments. Experimental cancer treatments are normally available only to people who participate in formal research programs, which are called clinical trials. Occasionally, a seriously ill person may be able to access an experimental drug through an expanded access program. Some of the treatments have regulatory approval for treating other conditions. Health insurance and publicly funded health care programs normally refuse to pay for experimental cancer treatments.

<span class="mw-page-title-main">Fas ligand</span> Protein-coding gene in the species Homo sapiens

Fas ligand is a type-II transmembrane protein expressed on various types of cells, including cytotoxic T lymphocytes, monocytes, neutrophils, breast epithelial cells, vascular endothelial cells and natural killer (NK) cells. It binds with its receptor, called FAS receptor and plays a crucial role in the regulation of the immune system and in induction of apoptosis, a programmed cell death.

<span class="mw-page-title-main">Apoptosome</span> A protein complex involved in the cellular apoptotic process.

The apoptosome is a large quaternary protein structure formed in the process of apoptosis. Its formation is triggered by the release of cytochrome c from the mitochondria in response to an internal (intrinsic) or external (extrinsic) cell death stimulus. Stimuli can vary from DNA damage and viral infection to developmental cues such as those leading to the degradation of a tadpole's tail.

α-Lactalbumin Protein-coding gene in the species Homo sapiens

α-Lactalbumin, also known as LALBA, is a protein that in humans is encoded by the LALBA gene.

<span class="mw-page-title-main">Death-inducing signaling complex</span>

The death-inducing signaling complex or DISC is a multi-protein complex formed by members of the death receptor family of apoptosis-inducing cellular receptors. A typical example is FasR, which forms the DISC upon trimerization as a result of its ligand (FasL) binding. The DISC is composed of the death receptor, FADD, and caspase 8. It transduces a downstream signal cascade resulting in apoptosis.

<span class="mw-page-title-main">FADD</span> Human protein and coding gene

FAS-associated death domain protein, also called MORT1, is encoded by the FADD gene on the 11q13.3 region of chromosome 11 in humans.

<span class="mw-page-title-main">Caspase 8</span> Protein found in humans

Caspase-8 is a caspase protein, encoded by the CASP8 gene. It most likely acts upon caspase-3. CASP8 orthologs have been identified in numerous mammals for which complete genome data are available. These unique orthologs are also present in birds.

Inhibitors of apoptosis are a group of proteins that mainly act on the intrinsic pathway that block programmed cell death, which can frequently lead to cancer or other effects for the cell if mutated or improperly regulated. Many of these inhibitors act to block caspases, a family of cysteine proteases that play an integral role in apoptosis. Some of these inhibitors include the Bcl-2 family, viral inhibitor crmA, and IAP's.

<span class="mw-page-title-main">XIAP</span> Protein-coding gene in the species Homo sapiens

X-linked inhibitor of apoptosis protein (XIAP), also known as inhibitor of apoptosis protein 3 (IAP3) and baculoviral IAP repeat-containing protein 4 (BIRC4), is a protein that stops apoptotic cell death. In humans, this protein (XIAP) is produced by a gene named XIAP gene located on the X chromosome.

<span class="mw-page-title-main">Caspase 3</span> Protein found in humans

Caspase-3 is a caspase protein that interacts with caspase-8 and caspase-9. It is encoded by the CASP3 gene. CASP3 orthologs have been identified in numerous mammals for which complete genome data are available. Unique orthologs are also present in birds, lizards, lissamphibians, and teleosts.

<span class="mw-page-title-main">Baculoviral IAP repeat-containing protein 3</span> Protein-coding gene in the species Homo sapiens

Baculoviral IAP repeat-containing protein3 is a protein that in humans is encoded by the BIRC3 gene.

<span class="mw-page-title-main">DFFA</span> Protein-coding gene in the species Homo sapiens

DNA fragmentation factor subunit alpha (DFFA), also known as Inhibitor of caspase-activated DNase (ICAD), is a protein that in humans is encoded by the DFFA gene.

<span class="mw-page-title-main">DLC1</span> Protein-coding gene in the species Homo sapiens

Deleted in Liver Cancer 1 also known as DLC1 and StAR-related lipid transfer protein 12 (STARD12) is a protein which in humans is encoded by the DLC1 gene.

<span class="mw-page-title-main">MADD (gene)</span> Protein-coding gene in the species Homo sapiens

MAP kinase-activating death domain protein is an enzyme that in humans is encoded by the MADD gene.

<span class="mw-page-title-main">BIRC7</span> Protein-coding gene in the species Homo sapiens

Baculoviral IAP repeat-containing protein 7 is a protein that in humans is encoded by the BIRC7 gene.

Anticancer genes exhibit a preferential ability to kill cancer cells while leaving healthy cells unharmed. This phenomenon is achieved through various processes such as apoptosis following a mitotic catastrophe, necrosis, and autophagy. In the late 1990s, extensive research in the field of cancer cells led to the discovery of anticancer genes. Mutations in these genes due to base substitutions leading to insertions, deletions, or alterations in missense amino acids can cause frameshifts, thereby altering the protein. A change in gene copy number or rearrangements is also essential for deregulating these genes. The loss or alteration of these anticancer genes due to mutations or rearrangements may lead to the development of cancer.

<span class="mw-page-title-main">Paraptosis</span> Type of programmed cell death distinct from apoptosis and necrosis

Paraptosis is a type of programmed cell death, morphologically distinct from apoptosis and necrosis. The defining features of paraptosis are cytoplasmic vacuolation, independent of caspase activation and inhibition, and lack of apoptotic morphology. Paraptosis lacks several of the hallmark characteristics of apoptosis, such as membrane blebbing, chromatin condensation, and nuclear fragmentation. Like apoptosis and other types of programmed cell death, the cell is involved in causing its own death, and gene expression is required. This is in contrast to necrosis, which is non-programmed cell death that results from injury to the cell.

Pharmaceutical innovations are currently guided by a patent system, the patent system protects the innovator of medicines for a period of time. The patent system does not currently stimulate innovation or pricing that provides access to medicine for those who need it the most, It provides for profitable innovation. As of 2014 about $140 Billion is spent on research and development of pharmaceuticals which produces 25–35 new drugs annually. Technology, which is transforming science, medicine, and research tools has increased the speed at which we can analyze data but we currently still must test the products which is a lengthy process. Differences in the performance of medical care may be due to variation in the introduction and circulation of pharmaceutical innovations.

Breastmilk medicine refers to the non-nutritional usage of human breast milk (HBM) as a medicine or therapy to cure diseases. Breastmilk is perceived as an important food that provides essential nutrition to infants. It also provides protection in terms of immunity by direct transfer of antibodies from mothers to infants. The immunity developed via this mean protects infants from diseases such as respiratory diseases, middle ear infections, and gastrointestinal diseases. HBM can also produce lifelong positive therapeutic effects on a number of chronic diseases, including diabetes mellitus, obesity, hyperlipidemia, hypertension, cardiovascular diseases, autoimmunity, and asthma.

References

  1. 1 2 3 4 Ho C S, J; Rydström, A; Trulsson, M; Bålfors, J; Storm, P; Puthia, M; Nadeem, A; Svanborg, C (Oct 2012). "HAMLET: functional properties and therapeutic potential". Future Oncology (London, England). 8 (10): 1301–13. doi:10.2217/fon.12.122. PMID   23130929.
  2. 1 2 Håkansson A, Zhivotovsky B, Orrenius S, Sabharwal H, Svanborg C (August 1995). "Apoptosis induced by a human milk protein". Proc. Natl. Acad. Sci. U.S.A. 92 (17): 8064–8. Bibcode:1995PNAS...92.8064H. doi: 10.1073/pnas.92.17.8064 . PMC   41287 . PMID   7644538.
  3. ↑ Svensson M, Håkansson A, Mossberg AK, Linse S, Svanborg C (April 2000). "Conversion of alpha-lactalbumin to a protein inducing apoptosis". Proc. Natl. Acad. Sci. U.S.A. 97 (8): 4221–6. Bibcode:2000PNAS...97.4221S. doi: 10.1073/pnas.97.8.4221 . PMC   18203 . PMID   10760289.
  4. ↑ Gustafsson L, Hallgren O, Mossberg AK, Pettersson J, Fischer W, Aronsson A, Svanborg C (May 2005). "HAMLET kills tumor cells by apoptosis: structure, cellular mechanisms, and therapy". J. Nutr. 135 (5): 1299–303. doi: 10.1093/jn/135.5.1299 . PMID   15867328.
  5. ↑ Pettersson-Kastberg J, Aits S, Gustafsson L, Mossberg A, Storm P, Trulsson M, Persson F, Mok KH, Svanborg C (2009). "Can misfolded proteins be beneficial? The HAMLET case". Ann. Med. 41 (3): 162–76. doi:10.1080/07853890802502614. PMID   18985467. S2CID   31198109.
  6. ↑ Halskau O, Underhaug J, Frøystein NA, Martínez A (June 2005). "Conformational flexibility of alpha-lactalbumin related to its membrane binding capacity". J. Mol. Biol. 349 (5): 1072–86. doi:10.1016/j.jmb.2005.04.020. PMID   15913646.
  7. ↑ Svanborg C, Agerstam H, Aronson A, Bjerkvig R, Düringer C, Fischer W, Gustafsson L, Hallgren O, Leijonhuvud I, Linse S, Mossberg AK, Nilsson H, Pettersson J, Svensson M (2003). "HAMLET kills tumor cells by an apoptosis-like mechanism--cellular, molecular, and therapeutic aspects". Adv. Cancer Res. Advances in Cancer Research. 88: 1–29. doi:10.1016/S0065-230X(03)88302-1. ISBN   9780120066889. PMID   12665051.
  8. ↑ Mok KH, Pettersson J, Orrenius S, Svanborg C (March 2007). "HAMLET, protein folding, and tumor cell death". Biochem. Biophys. Res. Commun. 354 (1): 1–7. doi:10.1016/j.bbrc.2006.12.167. PMID   17223074.
  9. ↑ Düringer C, Hamiche A, Gustafsson L, Kimura H, Svanborg C (October 2003). "HAMLET interacts with histones and chromatin in tumor cell nuclei". J. Biol. Chem. 278 (43): 42131–5. doi: 10.1074/jbc.M306462200 . PMID   12888554.
  10. ↑ Brest P, Gustafsson M, Mossberg AK, Gustafsson L, Duringer C, Hamiche A, Svanborg C (December 2007). "Histone deacetylase inhibitors promote the tumoricidal effect of HAMLET". Cancer Res. 67 (23): 11327–34. doi: 10.1158/0008-5472.CAN-07-1153 . PMID   18056459.
  11. ↑ Aits S, Gustafsson L, Hallgren O, Brest P, Gustafsson M, Trulsson M, Mossberg AK, Simon HU, Mograbi B, Svanborg C (March 2009). "HAMLET (human alpha-lactalbumin made lethal to tumor cells) triggers autophagic tumor cell death". Int. J. Cancer. 124 (5): 1008–19. doi: 10.1002/ijc.24076 . PMID   19048621.
  12. ↑ Marks, LR; Clementi, EA; Hakansson, AP (2013). "Sensitization of Staphylococcus aureus to Methicillin and Other Antibiotics In Vitro and In Vivo in the Presence of HAMLET". PLOS ONE. 8 (5): e63158. Bibcode:2013PLoSO...863158M. doi: 10.1371/journal.pone.0063158 . PMC   3641093 . PMID   23650551.
  13. ↑ Mossberg AK, Hou Y, Svensson M, Holmqvist B, Svanborg C (April 2010). "HAMLET treatment delays bladder cancer development". J. Urol. 183 (4): 1590–7. doi:10.1016/j.juro.2009.12.008. PMID   20172551.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.